LE6

(2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

Find entries where: LE6

is present as a standalone ligand in 1 entries

Find related ligands:

Chemical Component Summary
Name	(2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Synonyms	Dapagliflozin
Identifiers	(2~{S},3~{R},4~{R},5~{S},6~{R})-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Formula	C₂₁ H₂₅ Cl O₆
Molecular Weight	408.873
Type	NON-POLYMER
Isomeric SMILES	CCOc1ccc(cc1)Cc2cc(ccc2Cl)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O
InChI	InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
InChIKey	JVHXJTBJCFBINQ-ADAARDCZSA-N

Chemical Details
Formal Charge	0
Atom Count	53
Chiral Atom Count	5
Bond Count	55
Aromatic Bond Count	12

Drug Info: DrugBank

DrugBank ID	DB06292
Name	Dapagliflozin
Groups	approved
Description	Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2.[A261596] When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria.[A6757] Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents.[A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise.[L48251] It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021.[L48251]
Synonyms	Dapagliflozina Dapagliflozin (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol Dapagliflozin propanediol monohydrate
Brand Names	Qtern Taro-dapagliflozin Nat-dapagliflozin Farxiga Xigduo Accel-dapagliflozin Apo-dapagliflozin Dapagliflozin Qternmet XR Forxiga Pro-dapagliflozin Riva-dapagliflozin Ag-dapagliflozin Dapagliflozin Viatris Auro-dapagliflozin Edistride Auro-dapagliflozin / Metformin Nra-dapagliflozin Xigduo XR M-dapagliflozin Gln-dapagliflozin PMS-dapagliflozin Teva-dapagliflozin Apo-dapagliflozin-metformin Ebymect Dapagliflozin and Metformin Hydrochloride Jamp Dapagliflozin Sandoz Dapagliflozin
Indication	Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.[L46372,A6757,A6758]For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure.[L46372] Dapagliflozin is also indicated to either reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.[L46372] Combination products with dapagliflozin also exist, either as a dapagliflozin-saxagliptin or dapagliflozin-metformin hydrochloride formulation.[L38724,L38729] Both are used as an adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes.[L38724,L38729]
Categories	Alimentary Tract and Metabolism Benzene Derivatives Blood Glucose Lowering Agents Carbohydrates Cytochrome P-450 CYP1A2 Substrates Cytochrome P-450 CYP2A6 Substrates Cytochrome P-450 CYP2C9 Substrates Cytochrome P-450 CYP2D6 Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates Diuretics Drugs Used in Diabetes Glycosides Hypotensive Agents Oral Hypoglycemics P-glycoprotein substrates Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Sodium-Glucose Transport Proteins, antagonists & inhibitors Sodium-Glucose Transporter 2 Inhibitors UGT1A9 Substrates UGT2B7 substrates
ATC-Code	A10BK01 A10BD15 A10BD21 A10BD25
CAS number	461432-26-8

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Sodium/glucose cotransporter 2	MEEHTEAGSAPEMGAQKALIDNPADILVIAAYFLLVIGVGLWSMCRTNRG...	unknown	antagonist,inhibitor
UDP-glucuronosyltransferase 1-9	MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLIL...	unknown	substrate
UDP-glucuronosyltransferase 2B4	MSMKWTSALLLIQLSCYFSSGSCGKVLVWPTEFSHWMNIKTILDELVQRG...	unknown	substrate
UDP-glucuronosyltransferase 2B7	MSVKWTSVILLIQLSFCFSSGNCGKVLVWAAEYSHWMNIKTILDELIQRG...	unknown	substrate
Cytochrome P450 1A1	MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIG...	unknown	substrate
Cytochrome P450 1A2	MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...	unknown	substrate
Cytochrome P450 2A6	MLASGMLLVALLVCLTVMVLMSVWQQRKSKGKLPPGPTPLPFIGNYLQLN...	unknown	substrate
Cytochrome P450 2C9	MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...	unknown	substrate
Cytochrome P450 2D6	MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...	unknown	substrate
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
P-glycoprotein 1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	substrate
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682